Integra LifeSciences Reports Third Quarter 2020 Financial Results
Integra LifeSciences Holdings Corporation (IART) reported third-quarter 2020 revenues of $370.2 million, down 2.3% year-over-year but up 43.1% sequentially. GAAP earnings per diluted share were $0.38, reversing a loss from the prior year. Adjusted net income increased to $67.7 million, or $0.80 per share. The company maintained a strong financial position with $396 million in cash. However, full-year 2020 guidance remains withdrawn due to COVID-19 uncertainties impacting surgical volumes. Management expects further revenue improvement in Q4, barring significant pandemic setbacks.
- GAAP earnings per diluted share of $0.38 compared to a loss of ($0.32) in Q3 2019.
- Adjusted net income increased to $67.7 million, or $0.80 per share, from $58.7 million, or $0.68 per share, in the prior year.
- GAAP gross margin improved to 63.6% from 62.4% year-over-year.
- Adjusted EBITDA grew to $103.2 million, representing 27.9% of revenue, compared to 24.2% in the prior year.
- Reported revenues decreased 2.3% year-over-year and 1.5% on an organic basis.
- Full-year 2020 guidance remains withdrawn due to uncertainty around COVID-19.
PRINCETON, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2020.
Third Quarter 2020 Financial Summary
- Reported revenues were
$370.2 million , representing a decrease of2.3% on a reported basis and a decrease of1.5% on an organic basis compared to the prior year. These results were at the high end of the preliminary range provided on October 6, 2020;- Third quarter reported revenues increased
43.1% compared to the second quarter 2020;
- Third quarter reported revenues increased
- GAAP earnings per diluted share were
$0.38 , compared to a GAAP loss of ($0.32) in the third quarter of 2019. Adjusted earnings per diluted share were$0.80 , compared to$0.68 in the prior year; - The Company's full-year 2020 guidance remains withdrawn due to the uncertainty related to COVID-19 and ongoing variability in the recovery in surgical procedure volumes.
"Better than expected performance in the third quarter was driven by stronger recovery trends and solid execution across the organization," said Peter Arduini, Integra's president and chief executive officer. "I am proud of the ongoing commitment from our Integra colleagues, who are working tirelessly to deliver life-saving products to customers and patients. Barring significant worsening of the pandemic, we believe these efforts will result in a further sequential revenue improvement in the fourth quarter."
The Company reported GAAP gross margin of
Adjusted EBITDA for the third quarter of 2020 was
The Company reported GAAP net income of
Adjusted net income for the third quarter of 2020 was
Integra's financial position and liquidity remain strong. The Company ended the quarter with
On September 29, 2020, the Company announced it had entered into a definitive agreement to sell its Extremity Orthopedics business. The transaction is expected to close at or around the end of 2020, subject to the satisfaction of customary conditions including regulatory approvals and consultation with employee representative bodies.
2020 Full-Year Outlook
Due to the ongoing uncertainty around the scope and duration of the pandemic and the timing of recovery across the globe, the Company’s guidance for the full-year 2020 remains withdrawn. Barring significant worsening of the pandemic, the Company expects further sequential revenue improvement in the fourth quarter. The Company does not expect all markets or all product lines to improve at the same rate. The level and location of COVID-19 case emergence or recurrence and its associated impact on surgical procedure volumes and economic recovery, will shape the Company's financial progress.
Supplemental financial and operational information is included in a presentation that can be found in the "Investor" section of the Company's website at investor.integralife.com under "Events & Presentations".
In the future, the Company may record, or expects to record, gains or losses, expenses, or charges as described in the Discussion of Adjusted Financial Measures below, which will be excluded from the calculation of adjusted EBITDA, adjusted earnings per share for historical periods and in adjusted earnings per share guidance.
Conference Call and Presentation Available Online
Integra has scheduled a conference call for 8:30 a.m. ET today, Wednesday, October 28, 2020, to discuss financial results for the third quarter. The conference call will be hosted by Integra's senior management team and will be open to all listeners. Additional forward-looking information may be discussed in a question and answer session following the prepared remarks.
Integra's management team will reference a presentation during the conference call. The presentation can be found on investor.integralife.com.
Access to the live call is available by dialing (800) 353-6461 and using the passcode 9501226. The call can also be accessed via a webcast link provided on investor.integralife.com. A replay of the call will be available until November 2, 2020 by dialing (888) 203-1112 and using the passcode 9501226. The webcast will also be archived on the website.
About Integra
Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas®, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru®. For the latest news and information about Integra and its brands, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like “will,” “believe,” “may,” “could,” “would,” “might,” “possible,” “should,” “expect,” “intend,” “plan,” “anticipate,” or “continue,” the negative of these words, other terms of similar meaning or they may use future dates. Forward-looking statements contained in this news release include, but are not limited to, statements concerning the expected impact of COVID-19 on the Company; the impact of contingency plans and cost-savings measures; the Company’s liquidity and financial position; future financial performance, including projections for revenues, expected revenue growth (both reported and organic), GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, non-GAAP adjustments such as structural optimization charges, acquisition, divestiture and integration-related charges, COVID-19 related charges, EU Medical Device Regulation-related charges, litigation charges, discontinued product line charges, intangible asset amortization expense, convertible debt non-cash interest, expenses related to debt refinancing, and income tax expense (benefit) related to non-GAAP adjustments and other items. Statements of past performance, efforts, or results about which assumptions or inferences may be made can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, and may be outside of the company's control; these assumptions include, but are not limited to, when the impacts of COVID-19 may be the most severe and when and how the impacts of COVID-19 will subside. It is important to note that the Company’s goals and expectations are not predictions of actual performance. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to, the following: risks and uncertainties associated with medical epidemics or pandemics, such as the COVID-19 pandemic, including, without limitation, disruptions in operations, diversion of management and resources, the accuracy of procedural volume information, material cancellations and delays of procedures, reduced capital spending by healthcare institutions, impaired and disrupted global economic conditions relative to healthcare spending and access to credit markets, and delays in the development of clinical data and medical education, including data and education relevant to the impact of infectious disease on the use of the Company’s products; the Company's ability to execute its operating plan effectively; the Company’s ability to execute the sale of its extremities orthopedics business to Smith+Nephew, the Company’s ability to successfully integrate the Codman Neurosurgery business and other acquired businesses, including the realignment of acquired global sales territories; the Company's ability to manufacture and ship sufficient quantities of its products to meet its customers' demands; the ability of third-party suppliers to supply the Company with raw materials and finished products; global macroeconomic and political conditions; the Company's ability to manage its direct sales channels effectively; the sales performance of third-party distributors on whom the Company relies to generate revenue for certain products and geographic regions; the Company's ability to maintain relationships with customers of acquired entities and businesses; physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement for the Company's recently launched, planned and existing products; initiatives launched by the Company's competitors; downward pricing pressures from customers; the Company's ability to secure regulatory approval for products in development; the Company's ability to remediate quality systems violations; fluctuations in hospitals' spending for capital equipment; the Company's ability to comply with and obtain approvals for products of human origin and comply with regulations regarding products containing materials derived from animal sources; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the impact of goodwill and intangible asset impairment charges if future operating results of acquired businesses are significantly less than the results anticipated at the time of the acquisitions, the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the Company’s ability to achieve anticipated growth rates, margins and scale and execute its strategy generally; the amount and timing of acquisition and integration-related costs; the geographic distribution of where the Company generates its taxable income; the impact of legislation effecting healthcare reform in the United States and internationally; fluctuations in foreign currency exchange rates; the amount of our bank borrowings outstanding and other factors influencing liquidity; and the economic, competitive, governmental, technological, and other risk factors and uncertainties identified under the heading “Risk Factors” included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2019 and information contained in subsequent filings with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.
Discussion of Adjusted Financial Measures
In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted free cash flow conversion. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and product divestitures and discontinuances. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); and (v) those operating expenses also excluded from adjusted net income. The measure of adjusted net income consists of GAAP net income, excluding: (i) structural optimization charges; (ii) acquisition, divestiture and integration-related charges; (iii) COVID-19 related charges; (iv) EU Medical Device Regulation-related charges; (v) litigation charges; (vi) discontinued product lines charges; (vii) intangible asset amortization expense; (viii) convertible debt non-cash interest; (ix) expenses related to debt refinancing; and (x) income tax impact from adjustments. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. The measure of free cash flow consists of GAAP net cash provided by operating activities less purchases of property and equipment. The adjusted free cash flow conversion measure is calculated by dividing free cash flow by adjusted net income.
Reconciliations of GAAP revenues to organic revenues, GAAP adjusted net income to adjusted EBITDA and adjusted net income, and GAAP earnings per diluted share to adjusted earnings per diluted share all for the quarters ended September 30, 2020 and 2019, and the free cash flow and free cash flow conversion for the quarters ended September 30, 2020 and 2019, appear in the financial tables in this release.
The Company believes that the presentation of organic revenues and the other non-GAAP measures provide important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(In thousands, except per share amounts)
| Three Months Ended September 30, | |||||||||
| 2020 | 2019 | ||||||||
| Total revenues, net | $ | 370,232 | $ | 379,095 | |||||
| Costs and expenses: | |||||||||
| Cost of goods sold | 134,811 | 142,636 | |||||||
| Research and development | 19,460 | 19,003 | |||||||
| In-process research & development expense | — | 59,889 | |||||||
| Selling, general and administrative | 150,076 | 173,098 | |||||||
| Intangible asset amortization | 8,343 | 5,056 | |||||||
| Total costs and expenses | 312,690 | 399,682 | |||||||
| Operating income (loss) | 57,542 | (20,587 | ) | ||||||
| Interest income | 2,273 | 2,913 | |||||||
| Interest expense | (20,796 | ) | (13,962 | ) | |||||
| Other income, net | 2,492 | 4,127 | |||||||
| Income (loss) before taxes | 41,511 | (27,509 | ) | ||||||
| Income tax expense | 9,174 | 101 | |||||||
| Net income (loss) | $ | 32,337 | $ | (27,610 | ) | ||||
| Net income (loss) per share: | |||||||||
| Diluted net income (loss) per share | $ | 0.38 | $ | (0.32 | ) | ||||
| Weighted average common shares outstanding for diluted net income per share | 84,752 | 85,688 | |||||||
The following table presents revenues disaggregated by the major sources for the three months ended September 30, 2020 and 2019 (amounts in thousands):
| Three Months Ended September 30, | |||||
| 2020 | 2019 | Change | |||
| Neurosurgery | (2.9)% | ||||
| Instruments | 49,649 | 57,654 | (13.9)% | ||
| Total Codman Specialty Surgical(1) | (5.4)% | ||||
| Wound Reconstruction and Care | 82,115 | 82,213 | (0.1)% | ||
| Extremity Orthopedics | 21,922 | 20,852 | |||
| Private Label | 26,872 | 23,046 | |||
| Total Orthopedics and Tissue Technologies | |||||
| Total reported revenues | (2.3)% | ||||
| Impact of changes in currency exchange rates | (2,631) | — | |||
| Less contribution of revenues from divested products | (218) | (496) | |||
| Less contribution of revenues from discontinued products | (4,781) | (10,527) | |||
| Total organic revenues(2) | (1.5)% | ||||
(1) Prior period amounts were reclassified between categories within the Codman Specialty Surgical segment to conform to the current period presentation.
(2) Organic revenues have been adjusted to exclude foreign currency (current period), acquisitions and to account for divested and discontinued products.
Items included in GAAP net income and location where each item is recorded are as follows:
(In thousands)
Three Months Ended September 30, 2020
| Item | Total Amount | COGS(a) | SG&A(b) | R&D(c) | Amort.(d) | OI&E(e) | Tax(f) | ||||||
| Structural optimization charges | 4,543 | 491 | 3,875 | 177 | — | — | — | ||||||
| Acquisition, divestiture and integration-related charges(1) | 7,148 | 3,871 | 2,596 | 682 | — | — | — | ||||||
| COVID-19 related charges | (193) | 2 | (195) | — | — | — | — | ||||||
| EU Medical Device Regulation charges | 2,399 | 1,529 | 871 | — | — | — | — | ||||||
| Discontinued product lines charges | 999 | 999 | — | — | — | — | — | ||||||
| Intangible asset amortization expense | 20,180 | 11,837 | — | — | 8,343 | — | — | ||||||
| Convertible debt non-cash interest | 4,295 | — | — | — | — | 4,295 | — | ||||||
| Expenses related to debt refinancing | 3,428 | — | — | — | — | 3,428 | — | ||||||
| Estimated income tax impact from above adjustments and other items | (7,433) | — | — | — | — | — | (7,433) | ||||||
| Total adjustments | |||||||||||||
| Depreciation expense | 10,538 | — | — | — | — | — | — | ||||||
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, and Rebound Therapeutics acquisitions and the divestiture of extremity orthopedics and includes banking, legal, consulting, systems, and other expenses.
Three Months Ended September 30, 2019
(In thousands)
| Item | Total Amount | COGS (a) | SG&A (b) | R&D (c) | Amort. (d) | OI&E (e) | Tax (f) | ||||||
| Structural optimization charges | 5,353 | 1,055 | 3,794 | — | — | 504 | — | ||||||
| Acquisition and integration-related charges(1) | 74,531 | 1,804 | 12,838 | 59,889 | — | — | — | ||||||
| Litigation charges | (2,254) | — | 751 | — | — | (3,005) | — | ||||||
| EU Medical Device Regulation charges | 1,978 | — | 1,978 | — | — | — | — | ||||||
| Discontinued product line charges | 3,104 | 3,104 | — | — | — | — | — | ||||||
| Intangible asset amortization expense | 16,584 | 11,528 | — | — | 5,056 | — | — | ||||||
| Estimated income tax impact from above adjustments and other items | (12,939) | — | — | — | — | — | (12,939) | ||||||
| Total adjustments | |||||||||||||
| Depreciation expense | 10,367 | — | — | — | — | — | — | ||||||
a) COGS - Cost of goods sold
b) SG&A - Selling, general and administrative
c) R&D - Research & Development
d) Amort. - Intangible asset amortization
e) OI&E - Other income & expense
f) Tax - Income tax expense (benefit)
(1) Acquisition and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences and Rebound Therapeutics acquisitions and include banking, legal, consulting, systems, and other expenses. This includes a
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO ADJUSTED EBITDA
(UNAUDITED)
(In thousands)
| Three Months Ended September 30, | |||||||
| 2020 | 2019 | ||||||
| GAAP net income (loss) | $ | 32,337 | $ | (27,610 | ) | ||
| Non-GAAP adjustments: | |||||||
| Depreciation and intangible asset amortization expense | 30,718 | 26,951 | |||||
| Other (income), net | (2,492 | ) | (1,626 | ) | |||
| Interest expense, net | 10,800 | $ | 11,049 | ||||
| Income tax expense | 9,174 | $ | 101 | ||||
| Discontinued product lines charges | 999 | 3,104 | |||||
| Structural optimization charges | 4,543 | 5,353 | |||||
| Litigation charges | — | (2,254 | ) | ||||
| EU Medical Device Regulation charges | 2,399 | 1,978 | |||||
| Acquisition, divestiture and integration-related charges(1) | 7,148 | 74,531 | |||||
| COVID-19 related charges | (193 | ) | — | ||||
| Convertible debt non-cash interest | 4,295 | — | |||||
| Expenses related to debt refinancing | 3,428 | — | |||||
| Total of non-GAAP adjustments | 70,819 | 119,187 | |||||
| Adjusted EBITDA | $ | 103,156 | $ | 91,577 | |||
(1) Acquisition, divestiture and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, and Rebound Therapeutics acquisitions and the divestiture of extremity orthopedics and includes banking, legal, consulting, systems, and other expenses. The charges for the three months ended 2019 also include a
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE
(UNAUDITED)
(In thousands, except per share amounts)
| Three Months Ended September 30, | |||||||
| 2020 | 2019 | ||||||
| GAAP net income (loss) | ) | ||||||
| Non-GAAP adjustments: | |||||||
| Structural optimization charges | 4,543 | 5,353 | |||||
| Acquisition, divestiture and integration-related charges(1) | 7,148 | 74,531 | |||||
| COVID-19 related charges | (193 | ) | — | ||||
| EU Medical Device Regulation charges | 2,399 | 1,978 | |||||
| Litigation charges | — | (2,254 | ) | ||||
| Discontinued product lines charges | 999 | 3,104 | |||||
| Intangible asset amortization expense | 20,180 | 16,584 | |||||
| Expenses related to debt refinancing | 3,428 | — | |||||
| Convertible debt non-cash interest | 4,295 | — | |||||
| Estimated income tax impact from adjustments and other items | (7,433 | ) | (12,939 | ) | |||
| Total of non-GAAP adjustments | 35,366 | 86,357 | |||||
| Adjusted net income | $ | 67,703 | $ | 58,747 | |||
| Adjusted diluted net income per share | |||||||
| Weighted average common shares outstanding for diluted net income per share | 84,752 | 86,517 | |||||
(1) Acquisition and integration-related charges are associated with the Codman Neurosurgery, Arkis Biosciences, and Rebound Therapeutics acquisitions and the divestiture of extremity orthopedics and includes banking, legal, consulting, systems, and other expenses. The charges for the three months ended 2019 also include a
CONDENSED BALANCE SHEET DATA
(UNAUDITED)
(In thousands)
| September 30, | December 31, | ||||||
| 2020 | 2019 | ||||||
| Cash and cash equivalents | $ | 396,279 | $ | 198,911 | |||
| Accounts receivable, net | 218,184 | 275,296 | |||||
| Inventories, net (1) | 307,839 | 316,054 | |||||
| Current and long-term borrowing under senior credit facility | 966,602 | 1,243,561 | |||||
| Borrowings under securitization facility | 92,300 | 104,500 | |||||
| Long-term convertible securities | 469,898 | — | |||||
| Stockholders' equity | $ | 1,397,987 | $ | 1,416,736 | |||
(1) Inventories, net as of September 30, 2020 excludes
CONDENSED STATEMENT OF CASH FLOWS
(UNAUDITED)
(In thousands)
| Nine Months Ended September 30, | |||||||
| 2020 | 2019 | ||||||
| Net cash provided by operating activities | $ | 123,570 | $ | 142,249 | |||
| Net cash used in investing activities | (32,152 | ) | (142,059 | ) | |||
| Net cash provided by financing activities | 100,403 | 73,226 | |||||
| Effect of exchange rate changes on cash and cash equivalents | 5,547 | (4,273 | ) | ||||
| Net increase in cash and cash equivalents | $ | 197,368 | $ | 69,143 | |||
RECONCILIATION OF NON-GAAP ADJUSTMENTS - GAAP OPERATING CASH FLOW TO
MEASURES OF FREE CASH FLOW AND FREE CASH FLOW CONVERSION
(UNAUDITED)
(In thousands)
| Three Months Ended September 30, | ||||||
| 2020 | 2019 | |||||
| Net cash provided by operating activities | $ | 69,643 | $ | 64,240 | ||
| Purchases of property and equipment | (6,727 | ) | (13,593 | ) | ||
| Free cash flow | 62,916 | 50,647 | ||||
| Adjusted net income(1) | $ | 67,703 | $ | 58,747 | ||
| Adjusted free cash flow conversion | 92.9 | % | 86.2 | % | ||
| Twelve Months Ended September 30, | ||||||
| 2020 | 2019 | |||||
| Net cash provided by operating activities | $ | 212,757 | $ | 184,939 | ||
| Purchases of property and equipment | (52,657 | ) | (73,029 | ) | ||
| Adjusted free cash flow | 160,100 | 111,910 | ||||
| Adjusted net income(1) | $ | 196,266 | $ | 234,721 | ||
| Adjusted free cash flow conversion | 81.6 | % | 47.7 | % | ||
(1) Adjusted net income for quarters ended September 30, 2019 and 2020 are reconciled above. Adjusted net income for remaining quarters in the trailing twelve months calculation have been previously reconciled and are publicly available in the Quarterly Earnings Call Presentations on our website at investor.integralife.com under Events & Presentations.
The Company calculates adjusted free cash flow conversion by dividing its free cash flow by adjusted net income. The Company believes this measure is useful in evaluating the significance of the cash special charges in its adjusted earnings measures.
Investor Relations Contacts:
Michael Beaulieu
Director, Investor Relations
(609) 529-4812
michael.beaulieu@integralife.com
Media Contact:
Laurene Isip
Senior Director, Global Corporate Communications
(609) 750-7984
laurene.isip@integralife.com
FAQ
What were Integra LifeSciences' revenues for Q3 2020?
How did GAAP earnings per share change in Q3 2020?
What is Integra's guidance for the full year 2020?
What is the outlook for Q4 2020?
What was the adjusted net income for Q3 2020?
